{
  "meta": {
    "title": "25_Blood_Products_And_Transfusion_Reactions",
    "url": "https://brainandscalpel.vercel.app/25-blood-products-and-transfusion-reactions-831ee50f.html",
    "scrapedAt": "2025-11-30T12:33:32.349Z"
  },
  "questions": [
    {
      "text": "Choose the correct option regarding the storage temperatures of blood components.",
      "choices": [
        {
          "id": 1,
          "text": "RBC 20-22°C, Platelet 2-6°C, FFP -30°C"
        },
        {
          "id": 2,
          "text": "RBC 2-6°C,\tPlatelet 20-22°C, FFP -30°C"
        },
        {
          "id": 3,
          "text": "RBC -30°C,\tFFP 2-6\t°C,\tPlatelet 20-22°C"
        },
        {
          "id": 4,
          "text": "RBC 20-22°C, FFP below -30°C, Platelet 2-6 °C"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The recommended storage temperatures of different blood components is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Blood component</strong></td>\n<td><strong>Storage temperature</strong></td>\n</tr>\n<tr>\n<td>Whole blood and red blood cells</td>\n<td>2&ndash;6&deg;C</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma</td>\n<td>-30&deg;C or lower</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>Below -30&deg;C</td>\n</tr>\n<tr>\n<td>\n<p>Albumin</p>\n<p>Freeze-dried factor VIII</p>\n</td>\n<td>2&ndash;8&deg;C</td>\n</tr>\n<tr>\n<td>Platelet</td>\n<td>20&ndash;24&deg;C</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3513",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following can be used to store blood for up to 35 days?",
      "choices": [
        {
          "id": 1,
          "text": "Acid Citrate dextrose"
        },
        {
          "id": 2,
          "text": "Citrate phosphate dextrose"
        },
        {
          "id": 3,
          "text": "Citrate phosphate 2 dextrose"
        },
        {
          "id": 4,
          "text": "Citrate phosphate dextrose adenine - 1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Citrate dextrose phosphate adenine-1 (<strong>CDPA-1</strong>) can be used to store blood for up to <strong>35 days</strong>. It helps in <strong>improving ATP synthesis</strong> during storage. Hence, it increases the shelf life.</p>\n<p>The <strong>disadvantage</strong> of using CDPA-1 is that it increases <strong>uric acid stone</strong> formation.</p>\n<p>The shelf life of storage with other components are:</p>\n<ul>\n<li>Acid Citrate dextrose &ndash; 21 days</li>\n<li>Citrate-phosphate dextrose &ndash; 21 days</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9272",
      "difficulty": "medium"
    },
    {
      "text": "What is correct regarding transfusion of the blood received from blood bank?",
      "choices": [
        {
          "id": 1,
          "text": "It should be started within 4 hours of receiving it from the blood bank."
        },
        {
          "id": 2,
          "text": "It should be completed within 4 hours of receiving from the blood bank."
        },
        {
          "id": 3,
          "text": "No such time restraint and can be done anytime."
        },
        {
          "id": 4,
          "text": "It should be completed within 6 hours of receiving from the blood bank."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Blood received from blood bank should be completely transfused <strong>within 4 hours of receiving</strong>.</p>\n<p><strong>Principles </strong>of blood administration:</p>\n<ul>\n<li>All blood products should be given through an appropriate blood administration set containing a filter.</li>\n<li>A careful <strong>aseptic technique</strong> should be practised at all times.</li>\n<li><strong>Vital signs</strong> should be documented before and after transfusion and as clinically required. For the first 15 minutes after the infusion has begun, the patient should be kept under close observation to detect any signs of a serious transfusion reaction. If none is observed, the infusion rate may be increased.</li>\n<li>One unit of red cells is often given in <strong>1 to 4 hours</strong>, depending on the amount to be transfused and on the patient&rsquo;s cardiovascular status. Infusion of a unit for longer than 4 hours is not recommended, as there is a risk of bacterial proliferation because the opened unit is at room temperature.</li>\n<li>No other solution and no medication should be added to or infused through the same tubing as a blood product.</li>\n<li>Ringer&rsquo;s lactate or other solutions containing calcium must never be added to a blood product because the calcium present leads to coagulation.</li>\n<li>After the transfusion has been completed, the transfusion tag or record should become part of the patient&rsquo;s chart.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5325",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following patients receiving blood transfusions are more prone to develop bacterial sepsis?",
      "choices": [
        {
          "id": 1,
          "text": "A young women with severe anaemia"
        },
        {
          "id": 2,
          "text": "A patient with severe thrombocytopenia"
        },
        {
          "id": 3,
          "text": "A child with hemophilia A"
        },
        {
          "id": 4,
          "text": "A patient with vonWillebrand disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">Patients with <strong>thrombocytopenia</strong>&nbsp;receiving blood transfusions (<strong>platelets</strong>) are more prone to develop <strong>bacterial sepsis</strong>.&nbsp;</span></span></p>\n<p><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">Sepsis is mostly due to <strong>significant&nbsp;bacterial contamination</strong> of the blood products. <strong>Platelets</strong> have the <strong>maximum risk</strong> of causing this condition when compared to red cell preparations. Since patients with thrombocytopenia receive platelet transfusion, they are at an increased risk of infections.</span></span></p>\n<p><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">P</span></span><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">latelets (unlike red cells) must be <strong>stored </strong>at<strong> room temperature.&nbsp;</strong>This is a&nbsp;condition that is&nbsp;</span></span><strong><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW176042448\">favourable</span></span></strong><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">&nbsp;for <strong>bacterial</strong> <strong>proliferation</strong>. Broad-spectrum antibiotics must be started while waiting for the culture reports.</span></span></p>\n<p><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">The blood components that are preferred for the other conditions are:</span></span></p>\n<ul>\n<li><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">Anaemia - RBCs</span></span></li>\n<li><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">Hemophilia - FFP</span></span></li>\n<li><span class=\"TextRun SCXW176042448\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW176042448\">vonWillebrand disease - cryoprecipitate</span></span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0505",
      "difficulty": "medium"
    },
    {
      "text": "A patient has been brought with severe bleeding to your ER. His blood group is unknown. Fresh frozen plasma from which of the following blood groups can be given?",
      "choices": [
        {
          "id": 1,
          "text": "O"
        },
        {
          "id": 2,
          "text": "AB"
        },
        {
          "id": 3,
          "text": "B"
        },
        {
          "id": 4,
          "text": "A"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Fresh Frozen Plasma </strong>(FFP) from <strong>AB blood group</strong> can be given to this patient as it is the <strong>universal</strong> <strong>plasma donor</strong><strong>.&nbsp;</strong>AB plasma does not contain antibodies against antigens on RBCs of AB blood group.</p>\n<p><strong>O Rh-negative blood</strong> is the <strong>universal blood donor</strong>. It is used during emergency <strong>packed cell</strong> blood transfusion with an unknown blood group.&nbsp;It is preferred because it lacks the A and B and Rh antigens. Hence, it cannot be hemolyzed by anti-A, anti-B or anti-D antibodies in the recipient&rsquo;s blood.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7053",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common reaction occurring in patients undergoing blood transfusions?",
      "choices": [
        {
          "id": 1,
          "text": "Febrile hemolytic"
        },
        {
          "id": 2,
          "text": "Febrile non-hemolytic"
        },
        {
          "id": 3,
          "text": "Non-febrile hemolytic"
        },
        {
          "id": 4,
          "text": "Acute hemolytic"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>most common</strong> blood transfusion reaction is the <strong>febrile nonhemolytic</strong> reaction.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5880",
      "difficulty": "easy"
    },
    {
      "text": "Blood transfusion was started in a patient with severe anaemia. Within a few minutes she developed generalised pruritis, swelling of the tongue and stridor. Which antibody deficiency in the recipient most commonly causes this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Ig E"
        },
        {
          "id": 2,
          "text": "Ig A"
        },
        {
          "id": 3,
          "text": "Ig M"
        },
        {
          "id": 4,
          "text": "Ig G"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of severe, potentially <strong>fatal</strong>, <strong>allergic</strong> <strong>reactions</strong>.&nbsp;These are most likely to occur in patients with<strong>&nbsp;IgA&nbsp;deficiency</strong>.</p>\n<p>Such reactions&nbsp;may occur when blood products containing certain antigens are given to previously sensitized recipients. It is <strong>triggered</strong> by recipient&nbsp;<strong>IgG </strong>antibodies that <strong>recognize IgA</strong> in the infused blood product.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0501",
      "difficulty": "medium"
    },
    {
      "text": "Following blood transfusion in a post-operative patient, the following finding was noted. Which of the following is responsible for this reaction?",
      "choices": [
        {
          "id": 1,
          "text": "Ig E antibodies of donor"
        },
        {
          "id": 2,
          "text": "Ig E antibodies of recipient"
        },
        {
          "id": 3,
          "text": "Ig A antibodies of donor"
        },
        {
          "id": 4,
          "text": "Ig A antibodies of recipient"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">The given image, showing a raised and erythematous lesion, is suggestive of <strong>urticaria</strong>.&nbsp;</span></span><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">Such reactions may be triggered by the presence of an <strong>allergen</strong> in the <strong>donated blood</strong> product that is recognized by&nbsp;</span></span><strong><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW37143484\">IgE</span></span><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">&nbsp;antibodies </span></span></strong><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">in the </span></span><strong><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">recipient</span></span></strong><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">. </span></span></p>\n<p><span class=\"TextRun SCXW37143484\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW37143484\">These are mild reactions occurring more commonly in 1% to 3% of transfusions.</span></span></p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/531bd7294d3544d9aee6a23d8a105f14.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0502",
      "difficulty": "medium"
    },
    {
      "text": "A patient with thalassemia developed pallor and dizziness 1 week following blood transfusion. His lab reports are given below. Which of the following is seen in this condition?<div class='question-desc-html'><p>LDH - increased</p>\n<p>Haptoglobin - decreased</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Direct coombs test negative, IgG mediated"
        },
        {
          "id": 2,
          "text": "Direct Coombs test positive, IgG mediated"
        },
        {
          "id": 3,
          "text": "Direct coombs test negative, IgM mediated"
        },
        {
          "id": 4,
          "text": "Direct coombs test positive, IgM mediated"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of <strong>delayed hemolytic reaction</strong> following blood transfusion. It is<strong> IgG mediated</strong> and gives a <strong>positive</strong> result in <strong>direct Coombs</strong> test.</p>\n<p>These antibodies recognize foreign protein red cell antigens in a <strong>previously sensitized</strong> recipient (through a <strong>prior blood transfusion</strong>). They present with laboratory features of hemolysis like low&nbsp;haptoglobin level and elevated LDH.</p>\n<p><strong>Acute</strong>&nbsp;hemolytic&nbsp;reactions are usually&nbsp;caused by <strong>preformed</strong> <strong>IgM</strong>&nbsp;antibodies against <strong>donor red cells</strong> that fix complement.&nbsp;The direct Coombs test is usually positive.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/501b61befff74173bf910e5365684fa7x1280x1927.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0503",
      "difficulty": "medium"
    },
    {
      "text": "A patient who was admitted for blood transfusion developed transfusion-related acute lung injury. Which of the following statements is false about this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Pre-existing lung diseases are a risk factor"
        },
        {
          "id": 2,
          "text": "Incidence with platelet transfusion is more than that with whole blood"
        },
        {
          "id": 3,
          "text": "Symptoms develop after 2 days of transfusion"
        },
        {
          "id": 4,
          "text": "Subsequent transfusions from the same donor increases the incidence"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Transfusion-related acute lung injury (<strong>TRALI</strong>) is&nbsp;sudden-onset respiratory failure<strong>&nbsp;</strong>that<strong>&nbsp;</strong>occurs during or soon after the transfusion. It occurs&nbsp;<strong>within 6 hours</strong>, and not after 2 days following transfusion.</p>\n<p>TRALI is a severe fatal complication of blood transfusion.&nbsp;The incidence of TRALI is low (1 per 10,000 transfusions). However, it may occur <strong>more</strong> <strong>frequently </strong>in patients with<strong>&nbsp;preexisting&nbsp;lung disease</strong>.&nbsp;&nbsp;</p>\n<p>The pathogenesis involves a&nbsp;<strong>two-hit hypothesis</strong>:</p>\n<ul>\n<li>Priming event - increased sequestration and sensitization of neutrophils in the microvasculature of the lung</li>\n<li>Second hit - the factor (most commonly&nbsp;MHC class I antigens) present in the transfused blood product activates the primed neutrophils</li>\n</ul>\n<p>TRALI can occur in transfusions with all plasma-containing blood products. However, it is more likely to occur following the transfusion of&nbsp;<strong>fresh frozen plasma </strong>and<strong> platelets.&nbsp;</strong>This is because these&nbsp;products contain high levels of <strong>donor antibodies</strong>.&nbsp;&nbsp;</p>\n<p>Note: TRALI is important to recognize because&nbsp;donor products that induce complications in one patient are much more likely to do so in a second.&nbsp;Indeed, recent measures to <strong>exclude multiparous</strong> women from <strong>plasma donation</strong> have resulted in reduced incidence of TRALI.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0504",
      "difficulty": "medium"
    },
    {
      "text": "A 33-year-old man is receiving massive blood transfusion following a fall from height. 4 hours after transfusion, he becomes breathless and oxygen saturation decreases. Chest X-ray shows diffuse bilateral lung infiltrates. Which of the following statements is false regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Antibodies against MHC are associated"
        },
        {
          "id": 2,
          "text": "Treatment involves discontinuation of blood transfusion"
        },
        {
          "id": 3,
          "text": "Mortality rate is 5-10%"
        },
        {
          "id": 4,
          "text": "It is mediated by macrophages in lung vasculature"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of&nbsp;<strong>TRALI </strong>(transfusion-related acute lung injury). It is <strong>mediated by neutrophils</strong> entrapped in the lung vasculature.</p>\n<p><strong>Features</strong> of TRALI are:</p>\n<ul>\n<li>Fever</li>\n<li>Hypotension</li>\n<li>Hypoxemia</li>\n<li><strong>Bilateral pulmonary infiltrates -</strong>&nbsp;not responsive to diuretics</li>\n</ul>\n<p>Treatment is mainly supportive and blood transfusions are discontinued. The <strong>mortality&nbsp;rate</strong> in this condition is <strong>5-10%</strong>.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5886",
      "difficulty": "medium"
    },
    {
      "text": "A CKD patient had to undergo dialysis and his Hb was 5.2gm/dL. So two blood transfusions were to be given. The first bag was completed in 2 hours. The second was started and in the midway, he developed shortness of breath and hypertension. Vitals were BP - 180/120 mmHg and pulse rate - 110/min. What is the cause?",
      "choices": [
        {
          "id": 1,
          "text": "Allergic"
        },
        {
          "id": 2,
          "text": "Transfusion related circulatory overload"
        },
        {
          "id": 3,
          "text": "Transfusion-related acute lung injury"
        },
        {
          "id": 4,
          "text": "Febrile non-hemolytic transfusion reaction"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The given clinical scenario is suggestive of transfusion-associated circulatory overload (<strong>TACO</strong>).&nbsp;</span></p>\n<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">TACO is caused by</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">&nbsp;<strong>rapid</strong> or <strong>excess</strong> <strong>transfusion</strong> of red cell preparations or plasma products.&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">This condition is characterized by:</span></p>\n<ul>\n<li>Dyspnea with O2% &lt;90 at room air</li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Bilateral infiltrates on chest X-ray</span></li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Systolic hypertension</span></li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Elevation of brain natriuretic peptide, 1.5 times that of pre-transfusion levels</span></li>\n</ul>\n<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Administering the transfusion slowly, at the rate of 1 to 2 ml of blood/kg of body weight per hour.\\nDiuretics&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:8765,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;12&quot;:0,&quot;16&quot;:10}\">It can be <strong>prevented</strong> by administering the <strong>transfusion slowly</strong>, at the rate of 1 to 2 ml of blood/kg of body weight per hour. Diuretics are also used if necessary.&nbsp;</span></span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7681",
      "difficulty": "easy"
    },
    {
      "text": "A patient who receives recurrent transfusions for thalassemia develops fever and chills during this time. There is no evidence of hemolysis. Which of the following measures can decrease the rate of transfusion reactions?",
      "choices": [
        {
          "id": 1,
          "text": "Leukoreduced RBCs"
        },
        {
          "id": 2,
          "text": "Antibiotics"
        },
        {
          "id": 3,
          "text": "Irradiation"
        },
        {
          "id": 4,
          "text": "Washed RBCs"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The given scenario is suggestive of&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>febrile non-hemolytic transfusion reaction&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">(FNHTR)</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\">.</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>&nbsp;</strong>Such reactions can be <strong>prevented</strong> by using<strong> leukoreduced&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>RBCs.</strong></span></div>\n<div>Removal of leukocytes from the blood is called&nbsp;<strong>leukoreduction.</strong>&nbsp;It is done <strong>before storage </strong>to <strong>prevent</strong> <strong>cytokine</strong> formation.</div>\n<div>FNHTR<span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z h-lparen\"><strong>&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">may occur due to the following:</span></div>\n<ul class=\"listtype-bullet listindent1 list-bullet1\">\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Sensitization to the WBC antigens by previous blood transfusions or pregnancy</span></li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Cytokines produced by the donor leukocytes during storage</span></li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Bacterial contamination</span></li>\n</ul>\n<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Note:&nbsp;<strong>Luspatercept</strong> is an erythroid maturation agent, a receptor fusion protein consisting of a modified extracellular domain of human activin receptor type-2B linked to the human Ig-G1 Fc domain. The drug was recently approved by the FDA for the treatment of transfusion-dependent thalassemia.</span></p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7680",
      "difficulty": "easy"
    }
  ]
}